<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37080969</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology.</ArticleTitle><Pagination><StartPage>2176</StartPage><MedlinePgn>2176</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2176</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-37630-6</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) causes motor neuron degeneration, with 97% of cases exhibiting TDP-43 proteinopathy. Elucidating pathomechanisms has been hampered by disease heterogeneity and difficulties accessing motor neurons. Human induced pluripotent stem cell-derived motor neurons (iPSMNs) offer a solution; however, studies have typically been limited to underpowered cohorts. Here, we present a comprehensive compendium of 429 iPSMNs from 15 datasets, and 271 post-mortem spinal cord samples. Using reproducible bioinformatic workflows, we identify robust upregulation of p53 signalling in ALS in both iPSMNs and post-mortem spinal cord. p53 activation is greatest with C9orf72 repeat expansions but is weakest with SOD1 and FUS mutations. TDP-43 depletion potentiates p53 activation in both post-mortem neuronal nuclei and cell culture, thereby functionally linking p53 activation with TDP-43 depletion. ALS iPSMNs and post-mortem tissue display enrichment of splicing alterations, somatic mutations, and gene fusions, possibly contributing to the DNA damage response.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ziff</LastName><ForeName>Oliver J</ForeName><Initials>OJ</Initials><Identifier Source="ORCID">0000-0002-1504-7245</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. o.ziff@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK. o.ziff@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, WC1N 3BG, UK. o.ziff@ucl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neeves</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyzack</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-5730-2112</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Ruiz</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4817-0565</Identifier><AffiliationInfo><Affiliation>Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luisier</LastName><ForeName>Raphaelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Genomics and Health Informatics Group, Idiap Research Institute, Martigny, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarti</LastName><ForeName>Anob M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-6841-5718</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGranahan</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9537-4045</Identifier><AffiliationInfo><Affiliation>Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litchfield</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulton</LastName><ForeName>Simon J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-6936-6834</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7219-560X</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Humphrey</LastName><ForeName>Jack</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6274-6620</Identifier><AffiliationInfo><Affiliation>Nash Family Department of Neuroscience &amp; Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patani</LastName><ForeName>Rickie</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-3825-7675</Identifier><AffiliationInfo><Affiliation>The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK. rickie.patani@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, Queen Square Institute of Neurology, University College London, London, WC1N 3BG, UK. rickie.patani@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Hospital for Neurology and Neurosurgery, University College London NHS Foundation Trust, London, WC1N 3BG, UK. rickie.patani@ucl.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006591/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495901">TP53 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017398" MajorTopicYN="N">Alternative Splicing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002102" MajorTopicYN="N">Cadaver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004249" MajorTopicYN="N">DNA Damage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="Y">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050939" MajorTopicYN="N">Gene Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042822" MajorTopicYN="Y">Genomic Instability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>N.M. has stock options in and has consulted for Achilles Therapeutics and holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221). The remaining authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37080969</ArticleId><ArticleId IdType="pmc">PMC10119258</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-37630-6</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-37630-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2020;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PR, et al. The impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain. 2022;145:4440&#x2013;4447. doi: 10.1093/brain/awac279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac279</ArticleId><ArticleId IdType="pmc">PMC9762932</ArticleId><ArticleId IdType="pubmed">36162820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2021;92:510&#x2013;518. doi: 10.1136/jnnp-2020-325014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis. JAMA Neurol. 2019;76:1367&#x2013;1374. doi: 10.1001/jamaneurol.2019.2044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 2021;53:1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J. Neurol. Neurosurg. Psychiatry. 2010;81:1324&#x2013;1326. doi: 10.1136/jnnp.2010.207464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.207464</ArticleId><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia AM, et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 2017;7:10046. doi: 10.1038/s41598-017-10488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10488-7</ArticleId><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohawn DG, O&#x2019;Brien LC, Bennett JP., Jr. RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord. PLoS One. 2016;11:e0160520. doi: 10.1371/journal.pone.0160520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0160520</ArticleId><ArticleId IdType="pmc">PMC4972368</ArticleId><ArticleId IdType="pubmed">27487029</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, et al. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e829. doi: 10.1212/NXI.0000000000000829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000829</ArticleId><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey, J. et al. Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. Nat. Neurosci. 10.1038/s41593-022-01205-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36482247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappella M, Elouej S, Biferi MG. The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders. Front Cell Dev. Biol. 2021;9:662837. doi: 10.3389/fcell.2021.662837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.662837</ArticleId><ArticleId IdType="pmc">PMC8080375</ArticleId><ArticleId IdType="pubmed">33937264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C-Y, et al. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening. Molecules. 2020;25:2000. doi: 10.3390/molecules25082000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25082000</ArticleId><ArticleId IdType="pmc">PMC7221979</ArticleId><ArticleId IdType="pubmed">32344649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sances S, et al. Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat. Neurosci. 2016;19:542&#x2013;553. doi: 10.1038/nn.4273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4273</ArticleId><ArticleId IdType="pmc">PMC5015775</ArticleId><ArticleId IdType="pubmed">27021939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Maragakis NJ. Mini-Review: Induced Pluripotent Stem Cells and the Search for New Cell-Specific ALS Therapeutic Targets. Neurosci. Lett. 2021;755:135911. doi: 10.1016/j.neulet.2021.135911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135911</ArticleId><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Luisier R, et al. Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALS. Nat. Commun. 2018;9:2010. doi: 10.1038/s41467-018-04373-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04373-8</ArticleId><ArticleId IdType="pmc">PMC5964114</ArticleId><ArticleId IdType="pubmed">29789581</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, et al. CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs. Protein Cell. 2017;8:365&#x2013;378. doi: 10.1007/s13238-017-0397-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-017-0397-3</ArticleId><ArticleId IdType="pmc">PMC5413600</ArticleId><ArticleId IdType="pubmed">28401346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E, et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781&#x2013;795. doi: 10.1016/j.stem.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli K, et al. Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses. Nat. Commun. 2016;7:12143. doi: 10.1038/ncomms12143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12143</ArticleId><ArticleId IdType="pmc">PMC4935974</ArticleId><ArticleId IdType="pubmed">27378374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhinge A, Namboori SC, Zhang X, VanDongen AMJ, Stanton LW. Genetic Correction of SOD1 Mutant iPSCs Reveals ERK and JNK Activated AP1 as a Driver of Neurodegeneration in Amyotrophic Lateral Sclerosis. Stem Cell Rep. 2017;8:856&#x2013;869. doi: 10.1016/j.stemcr.2017.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.02.019</ArticleId><ArticleId IdType="pmc">PMC5390134</ArticleId><ArticleId IdType="pubmed">28366453</ArticleId></ArticleIdList></Reference><Reference><Citation>NeuroLINCS Consortium, et al. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. iScience. 2021;24:103221. doi: 10.1016/j.isci.2021.103221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103221</ArticleId><ArticleId IdType="pmc">PMC8554488</ArticleId><ArticleId IdType="pubmed">34746695</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi EG, et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat. Neurosci. 2022;25:226&#x2013;237. doi: 10.1038/s41593-021-01006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-01006-0</ArticleId><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, et al. Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. Nat. Neurosci. 2021;24:1673&#x2013;1685. doi: 10.1038/s41593-021-00944-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00944-z</ArticleId><ArticleId IdType="pmc">PMC8639773</ArticleId><ArticleId IdType="pubmed">34782793</ArticleId></ArticleIdList></Reference><Reference><Citation>Catanese A, et al. Synaptic disruption and CREB-regulated transcription are restored by K+ channel blockers in ALS. EMBO Mol. Med. 2021;13:e13131. doi: 10.15252/emmm.202013131.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202013131</ArticleId><ArticleId IdType="pmc">PMC8261490</ArticleId><ArticleId IdType="pubmed">34125498</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, et al. Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 2013;5:208ra149. doi: 10.1126/scitranslmed.3007529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007529</ArticleId><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Abo-Rady M, et al. Knocking out C9ORF72 Exacerbates Axonal Trafficking Defects Associated with Hexanucleotide Repeat Expansion and Reduces Levels of Heat Shock Proteins. Stem Cell Rep. 2020;14:390&#x2013;405. doi: 10.1016/j.stemcr.2020.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.01.010</ArticleId><ArticleId IdType="pmc">PMC7066330</ArticleId><ArticleId IdType="pubmed">32084385</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis R, et al. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis. Stem Cell Rep. 2017;9:1450&#x2013;1462. doi: 10.1016/j.stemcr.2017.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.09.004</ArticleId><ArticleId IdType="pmc">PMC5830977</ArticleId><ArticleId IdType="pubmed">28988989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins S, et al. Upregulation of &#x3b2;-catenin due to loss of miR-139 contributes to motor neuron death in amyotrophic lateral sclerosis. Stem Cell Rep. 2022;12:1650&#x2013;1665. doi: 10.1016/j.stemcr.2022.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.05.019</ArticleId><ArticleId IdType="pmc">PMC9287677</ArticleId><ArticleId IdType="pubmed">35750046</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z&#x2019;ev, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci. 2019;22:180&#x2013;190. doi: 10.1038/s41593-018-0293-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0293-z</ArticleId><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith AST, et al. Human Induced Pluripotent Stem Cell-Derived TDP-43 Mutant Neurons Exhibit Consistent Functional Phenotypes Across Multiple Gene Edited Lines Despite Transcriptomic and Splicing Discrepancies. Front Cell Dev. Biol. 2021;9:728707. doi: 10.3389/fcell.2021.728707.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.728707</ArticleId><ArticleId IdType="pmc">PMC8511491</ArticleId><ArticleId IdType="pubmed">34660586</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke, J. M. et al. RNase L-mediated RNA decay alters 3&#x2019; end formation and splicing of host mRNAs. bioRxiv10.1101/2022.01.28.478180 (2022).</Citation></Reference><Reference><Citation>Badia-i-Mompel P, et al. decoupleR: ensemble of computational methods to infer biological activities from omics data. Bioinforma. Adv. 2022;2:vbac016. doi: 10.1093/bioadv/vbac016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioadv/vbac016</ArticleId><ArticleId IdType="pmc">PMC9710656</ArticleId><ArticleId IdType="pubmed">36699385</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012;13:227&#x2013;232. doi: 10.1038/nrg3185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3185</ArticleId><ArticleId IdType="pmc">PMC3654667</ArticleId><ArticleId IdType="pubmed">22411467</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 2009;5:1512&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089977</ArticleId><ArticleId IdType="pubmed">20023718</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 2020;130:6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, et al. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421.e6. doi: 10.1016/j.celrep.2019.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.04.003</ArticleId><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019;29:1164&#x2013;1177.e5. doi: 10.1016/j.celrep.2019.09.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.09.066</ArticleId><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Appocher C, et al. Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells. Nucleic Acids Res. 2017;45:8026&#x2013;8045. doi: 10.1093/nar/gkx477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx477</ArticleId><ArticleId IdType="pmc">PMC5570092</ArticleId><ArticleId IdType="pubmed">28575377</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown A-L, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci. 2019;22:167&#x2013;179. doi: 10.1038/s41593-018-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0300-4</ArticleId><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Roczniak-Ferguson A, Ferguson SM. Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis. Life Sci. Alliance. 2019;2:e201900358. doi: 10.26508/lsa.201900358.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.201900358</ArticleId><ArticleId IdType="pmc">PMC6749094</ArticleId><ArticleId IdType="pubmed">31527135</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunker W, et al. TDP-43 prevents endogenous RNAs from triggering a lethal RIG-I-dependent interferon response. Cell Rep. 2021;35:108976. doi: 10.1016/j.celrep.2021.108976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108976</ArticleId><ArticleId IdType="pmc">PMC8109599</ArticleId><ArticleId IdType="pubmed">33852834</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M, et al. p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR) Cell. 2021;184:689&#x2013;708.e20. doi: 10.1016/j.cell.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7886018</ArticleId><ArticleId IdType="pubmed">33482083</ArticleId></ArticleIdList></Reference><Reference><Citation>Naro C, Bielli P, Pagliarini V, Sette C. The interplay between DNA damage response and RNA processing: the unexpected role of splicing factors as gatekeepers of genome stability. Front. Genet. 2015;6:142. doi: 10.3389/fgene.2015.00142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2015.00142</ArticleId><ArticleId IdType="pmc">PMC4397863</ArticleId><ArticleId IdType="pubmed">25926848</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero-Garcia J, et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. Elife. 2016;5:e11752. doi: 10.7554/eLife.11752.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.11752</ArticleId><ArticleId IdType="pmc">PMC4801060</ArticleId><ArticleId IdType="pubmed">26829591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaquero-Garcia, J. et al. RNA splicing analysis using heterogeneous and large RNA-seq datasets. bioRxiv 2021.11.03.467086 (2021) 10.1101/2021.11.03.467086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9984406</ArticleId><ArticleId IdType="pubmed">36869033</ArticleId></ArticleIdList></Reference><Reference><Citation>Slaff B, et al. MOCCASIN: a method for correcting for known and unknown confounders in RNA splicing analysis. Nat. Commun. 2021;12:3353. doi: 10.1038/s41467-021-23608-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23608-9</ArticleId><ArticleId IdType="pmc">PMC8184769</ArticleId><ArticleId IdType="pubmed">34099673</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiga A, et al. Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS. PLoS One. 2012;7:e43120. doi: 10.1371/journal.pone.0043120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043120</ArticleId><ArticleId IdType="pmc">PMC3416794</ArticleId><ArticleId IdType="pubmed">22900096</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurgeirsson B, Emanuelsson O, Lundeberg J. Sequencing degraded RNA addressed by 3&#x2019; tag counting. PLoS One. 2014;9:e91851. doi: 10.1371/journal.pone.0091851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0091851</ArticleId><ArticleId IdType="pmc">PMC3954844</ArticleId><ArticleId IdType="pubmed">24632678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenhuber ER, Lowe SW. Putting p53 in Context. Cell. 2017;170:1062&#x2013;1078. doi: 10.1016/j.cell.2017.08.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.08.028</ArticleId><ArticleId IdType="pmc">PMC5743327</ArticleId><ArticleId IdType="pubmed">28886379</ArticleId></ArticleIdList></Reference><Reference><Citation>Gore A, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011;471:63&#x2013;67. doi: 10.1038/nature09805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09805</ArticleId><ArticleId IdType="pmc">PMC3074107</ArticleId><ArticleId IdType="pubmed">21368825</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas BJ, et al. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213. doi: 10.1186/s13059-019-1842-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-019-1842-9</ArticleId><ArticleId IdType="pmc">PMC6802306</ArticleId><ArticleId IdType="pubmed">31639029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C-S, et al. Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency. Genome Res. 2014;24:25&#x2013;36. doi: 10.1101/gr.159483.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.159483.113</ArticleId><ArticleId IdType="pmc">PMC3875859</ArticleId><ArticleId IdType="pubmed">24131564</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, Atkin JD. DNA Damage, Defective DNA Repair, and Neurodegeneration in Amyotrophic Lateral Sclerosis. Front. Aging Neurosci. 2022;14:786420. doi: 10.3389/fnagi.2022.786420.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.786420</ArticleId><ArticleId IdType="pmc">PMC9093740</ArticleId><ArticleId IdType="pubmed">35572138</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D, Atkin JD. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017;26:2882&#x2013;2896. doi: 10.1093/hmg/ddx170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx170</ArticleId><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, et al. Poly(GR) in C9ORF72 -Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C, et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat. Neurosci. 2017;20:1225&#x2013;1235. doi: 10.1038/nn.4604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4604</ArticleId><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei Y, et al. Poly-glycine&#x2013;alanine exacerbates C9orf72 repeat expansion-mediated DNA damage via sequestration of phosphorylated ATM and loss of nuclear hnRNPA3. Acta Neuropathol. 2020;139:99&#x2013;118. doi: 10.1007/s00401-019-02082-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02082-0</ArticleId><ArticleId IdType="pmc">PMC6942035</ArticleId><ArticleId IdType="pubmed">31642962</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin LJ. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol. Dis. 2000;7:613&#x2013;622. doi: 10.1006/nbdi.2000.0314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0314</ArticleId><ArticleId IdType="pubmed">11114260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan S, Bowser R. p53 and Cell Cycle Proteins Participate in Spinal Motor Neuron Cell Death in ALS. Open Pathol. J. 2010;4:11&#x2013;22. doi: 10.2174/1874375701004010011.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874375701004010011</ArticleId><ArticleId IdType="pmc">PMC3092395</ArticleId><ArticleId IdType="pubmed">21572928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl Acad. Sci. U. S. A. 2019;116:4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Curle AJ, Haider AM, Balmus G. The role of DNA damage response in amyotrophic lateral sclerosis. Essays Biochem. 2020;64:847&#x2013;861. doi: 10.1042/EBC20200002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20200002</ArticleId><ArticleId IdType="pmc">PMC7588667</ArticleId><ArticleId IdType="pubmed">33078197</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice PS, et al. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve. 1996;19:797&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609941</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh AY, Martin LJ. DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. Neuromolecular Med. 2002;2:47&#x2013;60. doi: 10.1007/s12017-002-0038-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-002-0038-7</ArticleId><ArticleId IdType="pubmed">12230304</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill SJ, et al. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc. Natl Acad. Sci. U. S. A. 2016;113:E7701&#x2013;E7709. doi: 10.1073/pnas.1611673113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1611673113</ArticleId><ArticleId IdType="pmc">PMC5137757</ArticleId><ArticleId IdType="pubmed">27849576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K, Suzuki H, Aiso S, Matsuoka M. Overexpression of TDP-43 causes partially p53-dependent G2/M arrest and p53-independent cell death in HeLa cells. Neurosci. Lett. 2012;506:271&#x2013;276. doi: 10.1016/j.neulet.2011.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2011.11.021</ArticleId><ArticleId IdType="pubmed">22133803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MA, et al. TDP-43 induces p53-mediated cell death of cortical progenitors and immature neurons. Sci. Rep. 2018;8:1&#x2013;13. doi: 10.1038/s41598-018-26397-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26397-2</ArticleId><ArticleId IdType="pmc">PMC5970242</ArticleId><ArticleId IdType="pubmed">29802307</ArticleId></ArticleIdList></Reference><Reference><Citation>Folch J, et al. Role of cell cycle re-entry in neurons: a common apoptotic mechanism of neuronal cell death. Neurotox. Res. 2012;22:195&#x2013;207. doi: 10.1007/s12640-011-9277-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-011-9277-4</ArticleId><ArticleId IdType="pubmed">21965004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Guire C, Beyaert R, van Loo G. Death receptor signalling in central nervous system inflammation and demyelination. Trends Neurosci. 2011;34:619&#x2013;628. doi: 10.1016/j.tins.2011.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2011.09.002</ArticleId><ArticleId IdType="pubmed">21999927</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;29:636&#x2013;649.e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Kodavati M, Britz GW, Hegde ML. DNA Damage and Repair Deficiency in ALS/FTD-Associated Neurodegeneration: From Molecular Mechanisms to Therapeutic Implication. Front. Mol. Neurosci. 2021;14:784361. doi: 10.3389/fnmol.2021.784361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.784361</ArticleId><ArticleId IdType="pmc">PMC8716463</ArticleId><ArticleId IdType="pubmed">34975400</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target? Mech. Ageing Dev. 2017;161:163&#x2013;176. doi: 10.1016/j.mad.2016.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mad.2016.09.005</ArticleId><ArticleId IdType="pmc">PMC5316312</ArticleId><ArticleId IdType="pubmed">27663141</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, et al. Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer&#x2019;s patients. Cell Stem Cell. 2021;28:1533&#x2013;1548.e6. doi: 10.1016/j.stem.2021.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.04.004</ArticleId><ArticleId IdType="pmc">PMC8423435</ArticleId><ArticleId IdType="pubmed">33910058</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziff OJ, et al. Meta-analysis of human and mouse ALS astrocytes reveals multi-omic signatures of inflammatory reactive states. Genome Res. 2022;32:71&#x2013;84. doi: 10.1101/gr.275939.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.275939.121</ArticleId><ArticleId IdType="pmc">PMC8744676</ArticleId><ArticleId IdType="pubmed">34963663</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat. Rev. Neurol. 2017;13:96&#x2013;104. doi: 10.1038/nrneurol.2016.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2016.182</ArticleId><ArticleId IdType="pubmed">27982040</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat. Rev. Neurol. 2013;9:617&#x2013;628. doi: 10.1038/nrneurol.2013.203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer, D., Cordera, S., Cavalla, P. &amp; Migheli, A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139Suppl, 27&#x2013;33 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S, et al. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science. 2019;364:89&#x2013;93. doi: 10.1126/science.aav9776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav9776</ArticleId><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Atienzar S, et al. Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Sci. Adv. 2021;7:eabd9036. doi: 10.1126/sciadv.abd9036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd9036</ArticleId><ArticleId IdType="pmc">PMC7810371</ArticleId><ArticleId IdType="pubmed">33523907</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann C, et al. Automated and unbiased discrimination of ALS from control tissue at single cell resolution. Brain Pathol. 2021;3:e12937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412073</ArticleId><ArticleId IdType="pubmed">33576079</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y-M, et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann. Neurol. 2005;57:236&#x2013;251. doi: 10.1002/ana.20379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20379</ArticleId><ArticleId IdType="pubmed">15668976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewels PA, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 2020;38:276&#x2013;278. doi: 10.1038/s41587-020-0439-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0439-x</ArticleId><ArticleId IdType="pubmed">32055031</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayon T, Maizels RJ, Barrington C, Briscoe J. Single-cell transcriptome profiling of the human developing spinal cord reveals a conserved genetic programme with human-specific features. Development. 2021;148:dev199711. doi: 10.1242/dev.199711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.199711</ArticleId><ArticleId IdType="pmc">PMC8353162</ArticleId><ArticleId IdType="pubmed">34351410</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Risso D, Ngai J, Speed TP, Dudoit S. Normalization of RNA-seq data using factor analysis of control genes or samples. Nat. Biotechnol. 2014;32:896&#x2013;902. doi: 10.1038/nbt.2931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2931</ArticleId><ArticleId IdType="pmc">PMC4404308</ArticleId><ArticleId IdType="pubmed">25150836</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert M, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat. Commun. 2018;9:20. doi: 10.1038/s41467-017-02391-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02391-6</ArticleId><ArticleId IdType="pmc">PMC5750219</ArticleId><ArticleId IdType="pubmed">29295995</ArticleId></ArticleIdList></Reference><Reference><Citation>Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004;3:Article3. doi: 10.2202/1544-6115.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.2202/1544-6115.1027</ArticleId><ArticleId IdType="pubmed">16646809</ArticleId></ArticleIdList></Reference><Reference><Citation>Manders F, et al. MutationalPatterns: the one stop shop for the analysis of mutational processes. BMC Genomics. 2022;23:1&#x2013;18. doi: 10.1186/s12864-022-08357-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12864-022-08357-3</ArticleId><ArticleId IdType="pmc">PMC8845394</ArticleId><ArticleId IdType="pubmed">35168570</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>